New weight loss drug aims to keep weight off even after stopping taking it

Tanya Reynard | Last update: 30th September 2025

A new kind of weight loss jab?

Biotech company Resalis Therapeutics has announced that its weight loss drug RES-010 has entered Phase 1 human trials. But this isn’t just another appetite suppressant like Mounjaro and Wegovy.

RES-010 is an antisense oligonucleotide. This is a type of drug that blocks the activity of a molecule called miR-22, which controls key metabolic functions. By blocking miR-22, the drug helps the body shift how it stores and uses fat, promoting natural fat loss without reducing food intake.

What makes it different?

In animal trials (mice and non-human primates), RES-010:

• Triggered gradual but sustained fat loss
• Helped preserve lean muscle mass
• Crucially, prevented weight regain after treatment stopped, a common problem with GLP-1 drugs like Mounjaro

That last point is what has researchers most excited. Many SlimrChat users have told us their biggest concern is what happens when the jabs stop. RES-010 may hold the answer.

Drug developments in the weight loss field is moving fast, the huge impact drugs like Mounjaro and Wegovy have shown the thirst for their life-changing effects and the drugs will only improve, see the latest on the weight-loss pill, Orforglipron here

SlimrChat’s view

It’s early days. Human safety and efficacy still need to be proven. But if RES-010 delivers on its promise to change how the body handles fat, this could be the next generation of weight loss treatment.

We’ll be watching the trial results closely and will keep you updated.